Valnivudine

Summary

Valnivudine (CHEMBL4300944) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 497.6 Da · C27H35N3O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4300944
Name	Valnivudine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	16063377
Molecular formula	C27H35N3O6
Molecular weight	497.6
InChIKey	FJRRWJMFUNGZBJ-RBVMOCNTSA-N

SMILES: CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)[C@H]4C[C@@H]([C@H](O4)COC(=O)[C@H](C(C)C)N)O

IUPAC name: [(2R,3S,5R)-3-hydroxy-5-[2-oxo-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-3-yl]oxolan-2-yl]methyl (2S)-2-amino-3-methylbutanoate

Also known as: FV-100 FREE BASE, Valnivudina, Valnivudine, VALNIVUDINE

Parent form; salt/anhydrous children: CHEMBL4297380

Patent coverage: 1 distinct patent families (3 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).